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Abstract
Background: Histones and their post-translational modifications impact cellular function by acting as key regulators
in the maintenance and remodeling of chromatin, thus affecting transcription regulation either positively (activation)
or negatively (repression). In this study we describe a comprehensive, bottom-up proteomics approach to profiling
post-translational modifications (acetylation, mono-, di- and tri-methylation, phosphorylation, biotinylation,
ubiquitination, citrullination and ADP-ribosylation) in human macrophages, which are primary cells of the innate
immune system. As our knowledge expands, it becomes more evident that macrophages are a heterogeneous
population with potentially subtle differences in their responses to various stimuli driven by highly complex
epigenetic regulatory mechanisms.
Methods: To profile post-translational modifications (PTMs) of histones in macrophages we used two platforms of
liquid chromatography and mass spectrometry. One platform was based on Sciex5600 TripleTof and the second one
was based on VelosPro Orbitrap Elite ETD mass spectrometers.
Results: We provide side-by-side comparison of profiling using two mass spectrometric platforms, ion trap and qTOF,
coupled with the application of collisional induced and electron transfer dissociation. We show for the first time
methylation of a His residue in macrophages and demonstrate differences in histone PTMs between those currently
reported for macrophage cell lines and what we identified in primary cells. We have found a relatively low level of
histone PTMs in differentiated but resting human primary monocyte derived macrophages.
Conclusions: This study is the first comprehensive profiling of histone PTMs in primary human MDM. Our study
implies that epigenetic regulatory mechanisms operative in transformed cell lines and primary cells are overlapping
to a limited extent. Our mass spectrometric approach provides groundwork for the investigation of how histone PTMs
contribute to epigenetic regulation in primary human macrophages.
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Introduction
Post-translational modifications (PTM) of histones com-
prise the exceptionally complex system of epigenetic
regulation (“histone code”) of cellular functions. The
major source of complexity originates from multiple
combinations of homogenous and heterogeneous PTMs.
These modifications include acetylation, mono-, di- and
tri-methylation, phosphorylation, ubiquitination, ADP-
ribosylation, biotinylation and citrullination [1–3]. Never-
theless, histone PTMs are a universal mechanism of
regulation in the sense that they are also involved in
normal (healthy) cellular processes [4, 5]. When cells are
exposed to various external stimuli, i.e., toxins or toxic
substances, malignant transformation [6], bacterial [7] or
viral infections [8], the histone code changes, resulting in
phenotypic (functional) adaptations of the cells, which
may allow them to perform desired tasks or lead to a
pathological outcome [6, 9]. Because of the universality of
the histone code, it is necessary to establish a pattern of
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histone PTMs in cells that are considered to be in their
unaffected and resting physiological state before any
further manipulations are imposed. Therefore, our goal
in this study is to identify such a pattern in human
monocyte-derived macrophages (MDM).
Mononuclear phagocytes (MPs: monocytes, dendritic
cells, tissue macrophages, connective tissue histiocytes,
Langerhans cells of skin, Kupffer cells of liver, and micro-
glial cells of brain) comprise the principal elements of
the innate immune system [10–13]. Monocytes differen-
tiate to macrophages and dendritic cells, thereby replen-
ishing these cells under normal states, as well as respond
quickly to pro-inflammatory signals, infections or toxic
insults. They are produced in the bone marrow from
monoblasts, circulate in the bloodstream for a relatively
short period of time and eventually settle in tissues
throughout the body, where they differentiate into tissue
macrophages. Macrophages maintain homeostasis by
eliminating microbial pathogens and clearing debris, all
while responding to a variety of environmental stimuli.
Such stimuli leads to a variety of responses including
cell mobility, phagocytosis, antigen presentation, up-
regulation of secreted pro-inflammatory cytokines, react-
ive oxygen species, quinolinic acid, glutamate, arachidonic
acid, and its metabolites etc., thus contributing to the
overall response of the innate immune system [14–16].
Abnormalities in epigenetic regulatory processes will
eventually lead to damaging consequences in the function
of macrophages and their role as the first line of immune
defense. Despite decades of research, the mechanisms of
how microbes evade immune-surveillance as well as the
effect of other factors such as exposure to toxins, illicit
and other drugs etc., which contribute to a wide range of
impairments of the innate immune system, are still far
from being understood.
Most of the work done on investigating epigenetic
mechanisms resulting from histone PTMs in macro-
phages has been performed predominantly using three
cell lines: U937, THP1 and murine RAW264.7 [17–22].
The use of cell lines is common due to the fact that
using primary human cells as a model has experimental
limitations, such as inherent donor-to-donor variability
and relative resistance of primary macrophages to trans-
fection, a method ubiquitously used for mechanistic
studies. Nevertheless, MDMs are an attractive model as
they are more reflective of the in vivo response than
transformed cell lines. The intent of our study design
was to establish a baseline histone code for MDMs
under the physiological conditions of a resting cell as
the first step into deeper investigations of epigenetic
regulation occurring under various pathological condi-
tions. In this work, we present the first comprehensive
approach in profiling PTMs of histones isolated from
human MDMs obtained from healthy individuals.
Recently, mass spectrometry has been widely utilized
to profile PTMs of histones, providing direct informa-
tion on the site and types of modifications. In this study,
we used LTQ XL Orbitrap ETD (Thermo Scientific,
Inc.) and 5600 qTof/TripleTOF (ABSciex, Inc.) with two
methods of data acquisition utilizing collision induced
dissociation (CID) and electron transfer dissociation
(ETD) to yield complementary identifications of PTMs.
Although significant experimental work in mass spectro-
metric analysis of histone PTMs has been done, our data
indicates that some modifications identified in trans-
formed cell lines may not exist in primary cells, thus
building a foundation for further investigations of epi-




Acetonitrile (ACN), methanol, water (HPLC-gradient
grade), 0.1 % formic acid (FA) in water (v/v), and 0.1 %
formic acid in acetonitrile (Optima® LC/MS grade) were
purchased from Fisher Scientific (Fair Lawn, NJ, USA).
Acetic acid (99.7 + %, A.C.S. reagent), trifluoroacetic acid
(TFA, ReagentPlus®, 99 %), ammonium bicarbonate
(ReagentPlus®, 99 %) and iodoacetamide (IAA, Sigma
Ultra) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Dithiothreitol (DTT, molecular grade) and
modified trypsin (sequencing grade) were purchased
from Promega Corporation (Madison, WI, USA).
Sample preparation
Primary human monocytes were obtained by leukophor-
esis from donors who were seronegative for HIV-1, HIV-
2, and hepatitis B virus. Peripheral Blood Mononuclear
Cells (PBMC) from HIV-1, HIV-2 in full compliance and
approval of the University of Nebraska Medical Center
Institution Review Board. Monocytes were purified using
counter-current centrifugal elutriation and cultured at a
final concentration of 1 million per mL in macrophage
serum-free medium (M-SFM) purchased from Invitrogen®
(Carlsbad, CA, USA). M-SFM was supplemented with a
1 % HEPES buffer (4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid) also purchased from Invitrogen® (Grand
Island, NY, USA); 1 % Nutridoma was purchased from
Roche Diagnostics GmbH (Mannheim, Germany), and
Macrophage Colony Stimulating Factor (MCSF) was pur-
chased from PeproTech (Rocky Hill, NJ, USA). Half media
exchanges were performed on days 3 and 5 after seeding
cells.
Monocyte-derived macrophages (MDM) were harvested
on day 7. Proteins were fractionated using two different
approaches. In the first fractionation approach, we used a
Qproteome Nuclear Protein Kit (QIAGEN®, Hilden,
Germany). Each fraction - cytosolic, nuclear, and histone
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proteins - were quantified using the Pierce® 660 nm Pro-
tein Assay in a pre-diluted protein standard of Bovine
Serum Albumin (BSA), both from Thermo Scientific
(Rockford, IL, USA). The second fractionation approach
was acid extraction. Differentiated MDMs were washed
twice with ice-cold PBS and harvested with PBS contain-
ing 5 mM sodium butyrate. Following centrifugation at
2000 rpm for 5 min at 4 °C, the supernatant was removed
and cells were re-suspended in Triton Extraction Buffer
(TEB: PBS containing 0.5 % Triton X 100 (v/v), 2 mM
phenylmethylsulfonyl fluoride (PMSF) and 0.02 % (w/v)
NaN3). Cells were lysed for 10 min with gentle stirring,
then centrifuged at 2000 rpm for 10 min at 4 °C and
the supernatant was removed and discarded. Cells were
washed in half volume of TEB and centrifuged as before.
After that, the pellet was re-suspended in 0.2 M HCl and
kept overnight (16–18 h) at 4 °C with gentle stirring.
Following the overnight stirring, the sample was centri-
fuged at 2000 rpm for 10 min at 4 °C, the supernatant was
removed, and protein concentration was determined as
described previously.
The histone fraction isolated from MDMs was further
fractionated using a 1D gel electrophoresis system, XCell
SureLock™ Mini-Cell, which was purchased from Invi-
trogen®) (Life Technologies Corporation, Grand Island,
NY, USA), and connected with a PowerPac™ basic power
supply (Bio-Rad Laboratories Inc., Hercules, CA, USA).
For separation of histones, NuPAGE® 4–12 % Bis-Tris
Gel 1.0 mm was used (Invitrogen®, Carlsbad, CA, USA).
According to the manufacturer’s protocol, sample buffer
was prepared by adding 0.25 mL of NuPAGE® LDS
sample buffer (4×), 0.1 mL NuPAGE® sample-reducing
agent (10×), and 0.65 mL of HPLC-grade water (Fair
Lawn, NJ, USA). Samples were re-suspended in sample
buffer and heated for 5 min at 95 °C. Seven microliters
of SeeBlue® Plus2 pre-stained molecular mass marker
(Invitrogen®, Carlsbad, CA, USA) and 5 μg of histones
were loaded into the wells of the gel. Fractionation of
histones was performed under constant voltage (100 V)
for 90 min. After separation, the gel was removed from
the cassette and placed in a fixing solution (40 % metha-
nol or ethanol, 7 % acetic acid) for 1 h. After 1 h, the gel
was placed overnight in a staining solution of Brilliant
Blue G – Colloidal Concentrate Electrophoresis Reagent
(Sigma® Life Science, St. Louis, MO, USA). The staining
solution was prepared immediately before initiating
staining by combining four parts Brilliant Blue G to one
part methanol or ethanol. After an overnight treatment
in staining solution, the gel was immersed in de-staining
solution (10 % acetic acid, 25 % methanol or ethanol) for
60 s, rinsed briefly with 25 % methanol or ethanol, and
placed in 25 % methanol or ethanol overnight for further
de-staining. The gel was then scanned and bands were
excised prior to tryptic digestion.
Gel pieces were washed by placing them into plastic
vials with 100 μL of 50 % acetonitrile (ACN) and washed
for five minutes on a tilt table. After removing the wash
solution, 100 μL of 50 % ACN/50 mM ammonium bicar-
bonate (NH4HCO3) was added, and samples were washed
for 30 min on a tilt table. After removal of the second
wash solution, 100 μL of 50 % ACN/10 mM NH4HCO3
(Fisher A669-500) was added, and samples were washed
for 30 min on a tilt table. Following drying in a SpeedVac,
2 μL (0.1 μg/μL) of modified trypsin were added to the
prepared gel pieces in their vials and let to stand for 5–10
min in order to allow the enzyme/buffer solution to be
absorbed into the gels. Following this step, an additional
50 μL of 10 mM NH4HCO3 were added. Gels were incu-
bated in 37 °C for 18 h. Resulting peptides were extracted
by shaking at room temperature for 1 h in 100 μL of 0.1 %
trifluoroacetic acid in 60 % acetonitrile. This step was
repeated twice. Combined washes were then dried and re-
dissolved in 0.5 % TFA in water. Samples were cleaned up
using C18 u-ZipTip® pipette tips (EMD Millipore, Billerica,
MA, USA); the manufacturer-recommended protocol was
used in this step. Lastly, prior to mass spectrometry
analysis, samples were re-dissolved in 7 μL of 0.1 % formic
acid in water (v/v).
Mass spectrometry
Nano-LC-LTQ-Orbitrap
Samples were analyzed using a high resolution mass
spectrometry ESI-LC-MS/MS system in a nano-spray
configuration (LTQ Orbitrap XL, Thermo Scientific,
West Palm Beach, FL, USA) coupled with a nano-liquid
chromatography system (TEMPO™ nano MDLC System,
AB SCIEX, Framingham, MA, USA) equipped with two
alternating peptide traps and a PicoFrit RP-C18 column
(New Objectives, Woburn, MA, USA). The applied mass
spectrometer was tuned by direct infusion of angiotensin
and calibrated every 2 to 3 days using standards pro-
vided by the manufacturer.
Five microliters of each sample were loaded onto the
peptide trap with 98:2 (v/v) HPLC water with 0.1 % formic
acid: ACN with 0.1 % formic acid. The samples were then
eluted using a 60-minute linear gradient of 0–60 % of
acetonitrile in 0.1 % of formic acid.
The acquisition method was created in a data-dependent
mode with one full scan in the Orbitrap, followed by frag-
mentation of the five most-abundant peaks using CID/
ETD and peptide fragmentation in the linear ion trap
(LTQ). Resolution of the full scan in the Orbitrap was set
to 60,000 m/z with a range from 300 to 2000 Da. Precur-
sor peaks with a minimum signal count of 50,000 were
dynamically excluded after two fragmentations for 60 s
within a range of +/−10 ppm. Monoisotopic precursor
selection (MIPS) was enabled. Charge state rejection was
not used, but previously located background peaks were
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included in a mass rejection list. The collision energy
was set to 35 kV using an isolation width of 2 m/z
and an activation Q of 0.250.
chip-LC-5600 TripleTOF
Samples were analyzed using an ESI-LC-MS/MS system
in a nano-spray configuration (ABSciex 5600 Triple-
TOF®, AB SCIEX, Framingham, MA, USA) coupled with
an ultra-nano-HPLC with a cHiPLC system (Eksigent,
Dublin, CA, USA). Samples were loaded onto a 0.5 mm
C18 CL 3 μm 120 Å trap column (Eksigent, Dublin, CA,
USA), washed with 98:2 HPLC water with 0.1 % formic
acid: ACN with 0.1 % formic acid for 10 min and then
eluted through a 15 cm C18 CK 3 μm 120 Å ChromXP
column (Eksigent, Dublin, CA, USA) with 98:2 HPLC
water with 0.1 % formic acid: ACN with 0.1 % formic
acid using a 60-minute linear gradient of 0–60 % ACN
with 0.1 % formic acid. The instrument was calibrated
every 5–6 samples using 25 fmol of β-galactosidase
standards provided by the manufacturer. The acquisition
method was in the data dependent mode with one full
scan followed by fragmentation of the 50 most abundant
peaks. Precursor peaks with a minimum signal count of
100 were dynamically excluded after two selections for
6 s within a range ± 25 mDa. Charge states other than
2–5 were rejected. Rolling collision energy was used.
Propionylation
Chemical derivatization of histones by propionylation
was done following a protocol published by Garcia et al.
[23]. This process was done with 5 μg of the histone
fractions collected from MDMs with the QProteome
Nuclear Protein kit, as previously described. The proced-
ure consisted of four rounds of propionylation, with two
occurring before trypsin digestion and two after. Sam-
ples were dried down in a SpeedVac concentrator and
reconstituted in 5 μl of 100 mM ammonium bicarbonate
(Sigma A6141). Propionylation was then implemented
with the following sequence of steps: 1) 2 μl of ammo-
nium hydroxide (Sigma-Aldrich 338818) was added to
the samples, 2) 20 μl of fresh propionylation reagent,
which is composed of 75 % propionic anhydride (Alfa
Aesar A12955) and 25 % D0-methanol (Fisher A412P),
were added to the samples, mixed by vortex and briefly
spun down in a tabletop microcentrifuge, 3) pH was
tested with pH indicator strips and readjusted to 8 if
necessary with a drop-wise addition of ammonium hy-
droxide, 4) samples were incubated at 51 °C for 20 min,
5) samples were dried down to 5 μl in a SpeedVac
concentrator. The samples were then diluted in 5 μl of
100 mM ammonium bicarbonate and steps 1–5 were
repeated once. Next, 50 μl of 100 mM ammonium bicar-
bonate were added and the samples were incubated
overnight at 37 °C with a 1:20 (trypsin: protein) ratio of
sequencing-grade modified trypsin (Promega V511A).
Acetic acid was added in a drop-wise fashion to decrease
the pH to ≤3 and samples were briefly placed in −80 °C
to inactivate trypsin. Samples were dried down to 5 μl
and steps 1–5 were repeated once. Samples were then
diluted in 5 μl of 100 mM ammonium bicarbonate, steps
1–4 were completed a final time, and the resulting
peptides were dried down completely in a SpeedVac
concentrator.
The first round of sample cleanup was done using Oasis
mixed cation-exchange cartridges (Waters; Milford, MA).
The previously dried peptides were reconstituted in 1 ml
of 0.2 % formic acid. The pH was checked with pH indi-
cator strips and additional formic acid was slowly added
as necessary to lower the pH to ≤3. The MCX cartridge
was equilibrated by passing 1 ml of 1:1 methanol:water
across the cartridge. The sample was applied to the
column at a rate of ~1 drop per second. The cartridge
was then washed with 1 ml of wash solution, composed
of 5 % methanol (Fisher A412P) and 0.1 % formic acid in
water. A second wash was done with 1 ml of 100 %
methanol (Fisher A412P). Bound peptide was eluted with
1 ml of fresh elution buffer, composed of 50 μl of 28 %
NH4OH solution and 950 μl of methanol. Eluted peptides
were dried down completely in a SpeedVac concentrator.
The second round of sample cleanup was done using C18
u-ZipTip® pipette tips in accordance to the manufac-
turer’s protocol (Millipore, Billerica, MA). Peptides were
quantified on a NanoDrop2000 (Thermo Scientific,
Wilmington, DE) at 280 nm and 1 μg of each sample was
used for mass spectrometry analysis.
Identification of histone PTMs
Searches of PTMs were performed using three algo-
rithms: PEAKS 6.0 (Bioinformatics Solutions Incorpor-
ation, Waterloo, Canada), Mascot (Matrix Science, Boston,
MA), and ProteinPilot 5.0 (Ab Sciex, Framingham, MA).
The search parameters for PEAKS were as follows: 1) vari-
able modifications were carbamidomethylation on Cysteine
(C) and oxidation on methionine (M); 2) three missed
cleaved trypsin sites were permitted; 3) the mass accuracy
for the peptide (MS) was set at 10 ppm and for fragments
(MS/MS) at 0.8 Da; 4) false discovery rate (FDR) was
set at 1 %; 5) variable posttranslational modifications
were acetylation, mono-, di-, and tri-methylation, phos-
phorylation, biotinylation, ubiquitination, citrullination,
and ADP-ribosylation. The search parameters for Mascot
were as follows: 1) SwissProt 57.15 database was used; 2)
variable modifications were acetyl (Lys), acetyl (N-term),
carbamidomethyl (Cys), oxidation (His, Trp), propionyl
(Lys), propionyl (N-term) and propionyl (Ser); 3) mass
values were set to monoisotopic and the protein mass
was unrestricted; 4) the peptide mass tolerance was
set to ± 0.8 Da and the fragment mass tolerance was
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set to ± 0.5 Da; 5) a maximum of 1 missed cleavage was
allowed. The search parameters for ProteinPilot were
as follows: 1) paragon algorithm 5.0 was used; 2) special
factors were acetylation emphasis, propionylation pre-
digestion and propionylation post-digestion; 3) identifica-
tion focus was on biological modifications; 4) the search
effort was set to ‘thorough’.
Results and discussion
Extraction of histones
Histone octamers, composed of H2A, H2B, H3, and H4,
are essential for compacting DNA into a cell’s nuclei.
One octamer is used to wrap 146 bp and Histone H1
acts as a linker, wrapping an additional 20 bp, totaling
166 bp per one nucleosome. Considering that the hu-
man genome has approximately 3 × 109 bp, one would
need approximately 2 × 107 nucleosomes or 1.8 × 108 his-
tone molecules to wrap all the DNA [24], making histones
highly abundant proteins.
In this study we used two methods of histone isola-
tion, one using a Qproteome Nuclear Protein Kit and
the other using acid extraction. The kit method provides
a multistep protocol to isolate nuclei in the initial steps
and the insoluble nuclear protein fraction containing
histones, is isolated in the very last step. Based on our
studies (unpublished data), an average yield of nuclei
preparation from MDMs using this protocol is between
15 and 20 %. Protocols used by others also include isola-
tion of nuclei [25–27], which we consider as the major
yield-limiting step. The subsequent preparative step of
separating soluble nuclear proteins further contributes
to sample loss, although to a lesser extent. The yield of
histones is, on average, 12 μg from 1.2 × 107 MDM cells.
Technical and biological replicates of the histone yield
are presented in Table 1, showing a 24 % inter-variability
while intra-variability remains below 8 %, indicating
quite significant donor-to-donor variability. It is import-
ant to note that the human monocytes used in this study
are primary cells and cell cultures were normalized once
at the beginning by seeding 3 × 106 monocytes per well.
MDMs are adherent cells and the final number of adher-
ing and differentiating monocytes during a seven day
culture varies between donors, cultures, and plate wells.
This certainly contributes to substantial inter-variability.
In summary, based on the calculations presented above,
we estimate that the protocol, which includes isolation
of nuclei, yields a histone preparation of approxi-
mately 15 to 20 %.
Another method of histone preparation is acid extrac-
tion. We followed a protocol provided by Abcam, Inc.
(http://www.abcam.com/index.html?pageconfig=resource&
rid=11410), resulting in approximately four times more
yield of total proteins than the Qiagen protocol that
isolates nuclei. However, this resulting histone preparation
was not as pure compared to the fraction obtained from
the Qproteome Nuclear Protein Kit, as evaluated by 1-
dimensional gel electrophoresis (data not shown). The
purity of the histone fraction may have a less overall effect
when bottom-up analysis is preceded by 1-DE fractionation,
while for top-down analyses preceded by RP-HPLC frac-
tionation, the presence of non-pure histone fractions may
have a significant effect. Nevertheless, obtaining high yield
of histone preparation using primary cells remains a chal-
lenge. For collection of the data shown here, histones were
isolated using the Qiagen Qproteome Nuclear Protein Kit.
Enzymatic fragmentation of histones and sequence
coverage
Mixtures of isolated histones are commonly fractionated
by either RP-HPLC or 1-DE [28–30]. The first method
yields histones in solution, which can be used for top-down
proteomic analyses, while 1-DE fractionation implies in-gel
enzymatic digestion for bottom-up experiments. If the
latter method is used, the choice of enzyme for histone
digestion may have a profound effect. In this study,
we used trypsin, which is also used in a vast majority
of other proteomic experiments. Because histones are
basic proteins with high contents of Lys and Arg resi-
dues, the use of trypsin specific for peptide bonds C-
terminal to Lys and Arg (Lys-Pro and Arg-Pro bonds are
cleaved at very low rate) comes with the disadvantage
of cutting histones into short fragments of single amino
acids, di-, tri- and tetra-peptides. Such small peptides are
excluded from MS/MS analysis because molecular species
below 600 Da (or m/z 300+2) are not fragmented. On the
other hand, if Lys or Arg residues are acetylated or tri-
methylated, the C-terminal peptide bond is usually not
cleaved by trypsin. Our results (Table 2) show that while
using native histone preparations and trypsin digestion we
were able to obtain 50 % sequence coverage for Histone
Table 1 Intra- and inter-variability of histone yielda
Donor 1 Donor 2 Donor 3
Prep 1 [μg] 12.44 15.95 10.01
Prep 2 [μg] 10.78 14.91 9.23
Prep 3 [μg] 11.02 15.12 9.62
Intra-variability
Average [μg] 11.41 15.32 9.62
SD [μg] 0.90 0.55 0.39





aEach preparation used one 6-well plate corresponding to 12 × 106
seeded monocytes
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H2A, 91 % for Histone H2B, 61 % for Histone H3 and
81 % for Histone H4, and we identified most of the PTMs
reported based on analyses of preparations obtained from
cell lines. Use of other enzymes, such as chymotrypsin,
Arg-C, Glu-C, Asp-N [31] or other proteolytic enzymes
might provide more complete coverage by complementing
those sequences obtained using trypsin. Our previous
work evaluated use of chymotrypsin for histone analysis to
obtain almost complete sequence coverage; however, in
that study we used recombinant, non-modified histone
[28]. Although the extent of total sequence coverage of
histones is important, it is equally important to consider
which potentially modified residues were missed in our
mass spectrometric analysis. A comprehensive overview of
sequence coverage and identifications of PTMs resulting
from this study is presented in Table 2. The amino acids
highlighted in yellow are those that have been found to be
modified in this study, while those highlighted in green
have been reported as modified in other systems combined
per literature reports, but were not found in this study.
Segments of each histone sequence that have been identi-
fied by mass spectrometry in our study are underlined.
Further analysis of data provided in Table 2 shows that due
to limitations of our methodological approach, trypsin cuts
some regions into very small fragments due to the high
concentration of Lys and Arg residues. As a result, we
could potentially miss several modifications, including the
following: H2BK30, H3K56, H4S1, H4R3, H4K20 and
five modifications in the first eight N-terminally lo-
cated residues in histone H3.
Mass spectrometry profiling of PTMs
Tables 3, 4, 5 and 6 summarize PTMs identified for
Histone H2A, H2B, H3 and H4 during the course of
this study. These modifications are: acetylation (+42.01),
mono-, di- tri-methylation (+14.02, +28.03, +42.05), phos-
phorylation (+79.98), citrullination (+0.98) and ubiquitina-
tion (+114.04). We did not find biotinylation and ADP-
ribosylation, while several peptides were identified with
oxidated methionine. To exclude the effect of artificial
Table 2 Summary of PTM identification and sequence coverage of Histones H2A, H2B, H3 and H4 based on combined mass
spectrometric analysesa
aThe yellow highlighted amino acids we identified in this study as being modified. The green highlighted amino acids are reported in other literature and not
found in this study. The underlined sequences are what we identified in this study
Table 3 PTMs found in Histone H2A of resting macrophagea




23AGLQFPVGR31 + + +
85HLQLAIR91 + + +
85HLQLAVR(+14.02)91 +
92NDEELNK98 +
92NDEELNKLLGK102 + + +
92NDEELNKLLGR102 +
92GDEELDSLIK101 + + +
102ATIAGGGVIPHIHK115 + + +
102ATIAGGGAIPHIHK(+28.03)115 +
102VTIAQGGVLPNIQAVLLPK120 + + +
102VTIAQGGVLPNIQAVLLPK(+114.04)K121 +
aAcetylation: +42.01; Methylation: +14.02; Di-methylation: +28.03;
Ubiquitination: +114.04
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methylation during gel manipulation using acetic acid and
methanol for gel de-staining [32], we performed side-by-
side comparison by replacing methanol with ethanol in
our de-staining protocol. Methylated sites identified in
histones from gels exposed to methanol treatment but not
identified in histones exposed to ethanol treatment were
removed as methodological artifacts.
The next question we wanted to address was whether
PTMs reported in the literature and not found in our
study were missed due to an insufficient quantity of
histones to detect minimally present modifications or if
they do not exist in these cells at their resting stage. For
these MS analyses we used 5 μg of trypsin digested
histones, although, we also performed one analysis using
15 μg of histone preparation. As expected, an increased
amount of histone preparations used for analysis resulted
in an increased number of recorded spectra for already
identified peptides and their modifications. For example,
for 24DNIQGITKPAIR35 from Histone H4 we recorded
148 spectra when using 5 μg of preparation and 238 spec-
tra when 15 μg of protein were used. For the same peptide
with modification H4K31ac, the number of recorded spec-
tra increased from 5 to 12, respectively. Such an increase
of material used for mass spectrometry analyses allowed
us to identify only one more modification, which was
H2A98Kac in the 92NDEELNKLLGK102 peptide (Table 3),
while we identified the non-acetylated form of this peptide
using both amounts of histone preparation. Based on this
result we conclude that enrichment of tryptic digests of
histones and/or using more material for MS analysis may
potentially reveal additional PTMs, however we expect
that there will be very few of them and at a very low level
of abundance in resting macrophages. This situation may
change when macrophages become activated with highly
elevated cellular activity. Interestingly, we have found
only one Ser residue that was phosphorylated (H3S28ph;
Table 5) despite the higher extent of phosphorylated his-
tones reported in the literature. Simply increasing the
amount of material for MS analyses did not reveal more
phosphorylated sites. If such sites do exist, their detection
will certainly require sample enrichment using an en-
richment method, such as TiO2 columns [25].
Primary cells, in this case human MDM, are isolated
from various donors (individuals) and are characterized
Table 4 PTMs found in Histone H2B of resting macrophagea







34KESYSIYVYK43 + + +
34K(+42.01)ESYSVYVYK43 + + +
34K(+42.01)ESYSIYVYK43 + +
35ESYSVYVYK43 + + +
35ESYSIYVYK43 + + +
44VLKQVHPDTGISSK57 + + +
47QVHPDTGISSK57 + + +
58AMGIMNSFVNDIFER72 + + +
58AMGIMNSFVNDIFER72 + + +
73IAGEASR(+0.98)LAHYNK85 +
87STITSREIQTAVR99 + +
93EIQTAVR99 + + +
100LLLPGELAK108 + + +
109HAVSEGTKAVTKYTSAK125 + + +
aAcetylation: +42.01; Citrullination: +0.98; M: oxidated methionine
Table 5 PTMs found in Histone H3 of resting macrophagea











41YRPGTVALR49 + + +

















aAcetylation: +42.01; Methylation: +14.02; Di-methylation: +28.03; Tri-methylation:
+42.05; Phosphorylation: +79.97; Citrullination: +0.98; M: oxidated methionine
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by donor-to-donor variation including allelic polymorph-
ism. Therefore, the obtained data needs extra caution in
interpretation, but also may provide additional informa-
tion. For example, in Histone H2B (Table 4) we have
identified 34KESYSVYVYK43 peptide and its acetylated
form 34K(ac)ESYSVYVYK43 in all three donors. Interest-
ingly, we have also found 34KESYSIYVYK43 peptide with
Val to Ile substitution and its acetylation form 34K(ac)ESY-
SIYVYK43. In this case, all three donors have the same
Val to Ile substitution, but it might not be the case if
cells from other donors are used. This latter finding shows
that the epigenetic effect of allelic polymorphism, which
has been well documented [33, 34], needs to be consid-
ered in data interpretation if such polymorphism affects
residues that can be potentially modified.
Although our experimental data showed a degree of
conserved acetylated and methylated Lys residues in
histones, many studies involving histone PTMs have
been done to date using transformed cell lines such as
Jurkat, U937, HeLa etc. [31, 35, 36] and little has been
done using primary human cells. Although human trans-
formed cell lines reflect mechanisms operative in pri-
mary human cells, substantial effort is required to prove
experimentally the degree of histone code conservation
between transformed and primary cells. An advantage of
using cell lines is an almost unlimited amount of ma-
terial that can be obtained for experiments, while the
number of primary cells from donors is definitively
limited. In addition, primary cells obtained from various
donors will certainly represent inherent variability exist-
ing within any population of individuals, while cell lines
typically represent one individual who served as a donor,
very often in the distant past such as in the case of HeLa
cells [37]. Regardless of known drawbacks, MDMs are
still an attractive primary cell model as they reflect the
in vivo response much closer than transformed cell lines.
Another advantage of mass spectrometric profiling of
histone PTMs is that despite sharing specific modifica-
tion(s), the overall modification pattern of a specific
histone region might be different, thus its regulatory
effect may vary. Figure 1 shows an example of such
pattern differences for N-terminal tails of histones H3
and H4. Although enzymes may modify many of the
same residues on histones, the substrate specificity or
selectivity for modifications at particular sites is not
clear. Moreover, it is not clear whether patterns pre-
sented in Fig. 1 result in differential modifications or
differential removal of specific groups. Addressing the
order and/or dynamic of histone PTMs would require
various experimental approaches including measurements
of activity and cellular location of modifying enzymes [38]
leading to defining the role of such distinct patterns in
transcriptional regulation [39]. To further complicate
matters, it is possible that the modification of one site
is dependent on the modification or lack of modifica-
tion of another site, as has been shown for ubiquiti-
nation of the H2BK120ub residue and tri-methylation
of the H3K49(me3) and bH3K79(me3) residues [19].
This gives evidence that PTM cross-talk is emerging
and gaining importance in the interpretation of regu-
latory effects.
The majority of the data generated from this study was
provided by a combination of qTof/Triple TOF (ABSciex)
and LTQ XL Orbitrap with CID (Thermo) systems,
except for ubiquitination, which was identified only using
LTQ XL Orbitrap with ETD method. The latter could be
due to the fragile nature of ubiquitination and the ETD
providing a gentler fragmentation, whereas CID fragmen-
tation in both the qTOF and Orbitrap is more energetic,











24DNIQGITKPAIR35 + + +
24DNIQGITKPAIRR36 +
24DNIQGITK(+42.01)PAIR35 + +
45RISGLIYEETR54 + + +
45R(+0.98)ISGLIYEETR55 +
46ISGLIYEETR54 + + +
46ISGLIYEETR(+14.02)54 + +
46ISGLIYEET(+114.04)R(+28.03)54 +
60VFLENVIR67 + + +




79KTVTAMDVVYALK91 + + +
79K(+42.01)TVTAMDVVYALK91 +
80TVTAMDVVYALK91 + + +
80TVTAMDVVYALK91 + + +
80TVTAMDVVYALKR92 +
80TVTAMDVVYALKR92 + + +
93QGRTLYGFGG102 + +
96TLYGFGG102 + +
aAcetylation: +42.01; Methylation: +14.02; Di-methylation: +28.03; Citrullination:
+0.98; Ubiquitination: +114.04; M: oxidated methionine
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producing more signature transitions for overall iden-
tifications of modified peptides. Therefore, it is beneficial
to use complementary mass spectrometry platforms and
methods of data acquisition to increase sequence and
PTM coverage. As dependent as identification of acetyl-
ation and methylation is on the amount of material, we
expect sample enrichment techniques such as TiO2
columns/cartridges to broaden identification of phos-
phorylated peptides. Immunoprecipitation using a specific
antibody will apply to the detection of ubiquitinated
peptides.
C-terminal peptide bonds of lysine residues are cleaved
by trypsin unless ε-amine is blocked by acetylation.
Therefore, unmodified histones rich in lysine residues
are fragmented into short peptides. Propionylation of
ε-amines prevents trypsin from cleaving these peptide
bonds and allows non-modified Lys and to be identi-
fied by mass spectrometry. In this study, we performed
propionylation of Histone H3 before and after trypsin
digestion, followed by mass spectrometry analysis. We
found peptides with propionylated Lys residues at posi-
tions 4, 9, 14 and 18 (Fig. 2). This result combined with
detecting acetylated Lys residues shows that Lys at pos-
ition 4 is indeed not modified in resting primary macro-
phages and that some Lys residues at positions 9, 14 and
18 are not acetylated, thus contributing to the complex
mosaic of PTMs in this region. The exact ratio of acetyl-
ation of Lys residues in this particular region of Histone
H3 will be subjected to a separate and more focused
study.
Histidine (His) methylation
Herein, we report, for the first time, methylation of
His at position 75 in Histone H4 in primary human
MDM. Figure 3 shows mass spectrum of 68DAVTYTEH
(+14.02)AK77 modified by adding mass of 14 Da to His.
Identification of this PTM was detected using qTOF (AB
Sciex 5600 TripleTof) with all transitions lined-up without
significant deviation from their theoretical (expected)
mass.
In 1972, Borun and colleagues demonstrated that His
is methylated in histones during the HeLa S-3 cell cycle
[40]. Since then, His methylation has been found in a
variety of proteins [41–44], however, for many years,
protein methylation was outside mainstream research in-
terests, mostly because of its unclear role in biological
processes. Since the mid-1990s, Lys and Arg methylation
have gained significant attention as a result of general
progress in research describing the biological importance
of this specific PTM [45]. Nevertheless, the role of His
methylation in the regulation of biological processes is
lagging and a relatively small number of studies have been
published. Boffa et al. reported that carcinogens, such as
alkylating carcinogen 1,2-dimethylhydrazine (DMH), in-
duces colonic tumors and leads to non-random methyla-
tion of His in Histone H1, which is not normally seen in
Fig. 1 Variability of PTM patterns in N-terminal regions of histones H3 and H4. Although some modifications are shared by more than one pattern,
each of them likely represents different regulatory mechanisms
Fig. 2 Propionylation. Identification of propionylated Lys residues (marked with *) in histone H3. All propionylated sites were found in histone
preparations from resting MDMs of four donors
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this protein [46, 47]. The role of H4H75me1 in epigenetic
regulation is intriguing and we are pursuing it in subse-
quent studies, particularly because in a concurrent study
we have documented the novel observation of a significant
decrease of this modification when MDMs were exposed
to chemical stress (data not shown here).
Ubiquitination and citrullination
A major advantage of the ETD method of data acquisition
is the ability to identify ubiquitination. In this study, we
found H2AK120 ubiquitinated (H2AV isoform, UniProt#
Q71UI9) and the corresponding mass spectrum is shown
in Fig. 4. The position of the ubiquitinated Lys residue is
always the first in a doublet of Lys-Lys di-peptides;
however, its numerical position may be different depend-
ing on the isoform (see Additional file 1: Table S1) specific
to a particular donor. Nevertheless, this ubiquitinated
Lys corresponds to H2AK119, which is found in other
cells such as yeast or the RAW264.7 mouse monocytes/
macrophage cell line [48]. Ubiquitination of H2AK120 is
commonly observed [49] and it has also been shown to be
associated with transcriptional repression of chemo-
kines or chemokine ligands such as CCL5, CXCL10 and
CXCL2, however not CXCL1 [48]. Another ubiquitinated
site found in our study was H4T54ub, which was detected
in conjunction with H4R55me2 modification and assign-
ment of transitions from ETD MS/MS reported high
confidence. Our mass spectrometric analysis did not
confirm the presence of H2BK120ub, which was found in
the U937 human leukemia cell line [50].
Citrullination is an enzymatic deamination of protein
bound arginine by peptidylarginine deiminases (PAD)
and is considered as a PTM with an additional mass of
0.98 Da. We have identified the following five peptides
with citrullination (arginine deimination) modifications:
1) 73IAGEASR(+0.98)LAHYNK85 from Histone H2B,
2) 70LVR(+0.98)EIAQDFK79, 3) 116R(+0.98)VTIMPK122
from Histone H3, 4) 21VLR(+0.98)DNIQGITK31, and
5) 45R(+0.98)ISGLIYEETR55 from Histone H4. Dimethyla-
tion prevents Arg from being deiminated by PAD, however,
Fig. 3 Identification of His monomethylation. MS/MS spectrum of Histone H4 peptides marked with mono-methylated histidine acquired using
qTOF. a Peptide sequence and assignment of y and b transitions; b Spectrum with corresponding assignment of amino acids; c Mass error for
fragment ions assignment
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mono-methylated Arg can be deiminated and converted to
citrullin [51]. Because mono-methylation is associated
with transcription activation, citrullination preventing Arg
methylation is considered as a transcription repressor.
Conclusions
This study is the first comprehensive profiling of histone
PTMs in primary human MDM. Monocytes were grown
in the presence of MCSF to support differentiation to
macrophages. Although this could be considered as stimu-
lation, we consider this state of MDMs as resting and any
subsequent activation would be considered as a response
to external stimuli such as cytokines, microbial products,
viral infection and inflammation. Although MDMs main-
tain their metabolism, we may expect relatively low levels
of PTMs to promote transcription and relatively high
levels of PTMs responsible for transcription suppression.
In support of this conclusion, we observed as many
as five Arg residues being deimidated (converted to citrul-
lin) in Histones H2B, H3 and H4, which are considered
transcription repressors.
Some regions of histones, i.e., N-terminal tail of H3,
contain multiple Lys and Arg residues either next to each
other or apart by one or two other amino acids. When
digested with trypsin, they yield very short peptides or
single amino acids, which are not recorded using the
standard data dependent acquisition mass spectrometry
method. One exception is the acetylation of Lys, which
protects the peptide bond from trypsin digestion. In these
situations, specific antibodies have an edge in detecting
changes.
Methylation of His residues in histones is rarely ob-
served; therefore, our identification of methylated His at
position 75 in Histone H4 can be considered quite novel.
Potential regulatory functions of this modification remain
highly speculative, yet intriguing, and will require future
investigations. Further studies of this histone modification
are warranted and will shed new light on how it may con-
tribute to the epigenetic regulation of resting and activated
macrophage.
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